lobbying_activities: 2338884
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2338884 | 471b28a9-b610-4315-a773-331d61786141 | 3A | NATIONAL COMMITTEE TO PRESERVE SOCIAL SECURITY AND MEDICARE | 27467 | NATIONAL COMMITTEE TO PRESERVE SOCIAL SECURITY AND MEDICARE | 2019 | third_quarter | MMM | Drug Pricing. H.R. 3, the Lower Drug Costs Now Act: Proposals to authorize the Secretary of Health and Human Services (HHS) to negotiate drug prices on behalf of Medicare with pharmaceutical manufactureres. Create a maximum price for any negotiated drug with an international price index (Average International Market price). Require drug manufacturers that refuse to negotiation with HHS to pay a Non-Compliance Fee of 65 percent of the gross sales of the drug in question. Require drug companies that raised the price of a drug in Medicare above the rate of inflation since 2016 to either lower the price or pay the entire price above inflation in a rebate back to the Treasury. Create a $2,000 Medicare beneficiary annual out-of-pocket cost cap for prescription drugs. Drug Pricing. S. 2543, the Prescription Drug Pricing Reduction Act of 2019: Require pharmaceutical manufacturers to rebate Medicare if they raise their prices for drugs covered by Medicare Parts B and D faster than inflation. Establish an out-of-pocket spending limit in which Medicare beneficiaries would pay no more than $3,100 a year on drug costs. Require Medicare Part D private insurers to pay 60 percent and, drug makers 20 percent, of the costs incurred over the out-of-pocket spending cap. Increase transparency into pharmacy benefit manager practices and manufacturer drug pricing decisions. Provide state Medicaid programs with more authority to contain drug prices. Drug Pricing. H.R. 1046, the Medicare Negotiation and Competitive Licensing Act: Proposal to allow the Secretary of Health and Human Services to directly negotiate prices for prescription drugs and issue a competitive license allowing other manufacturers to produce the drug for Medicare in the event negotiations fail. Drug Pricing. S. 1895, the Lower Health Care Costs Act of 2019: Proposals to reduce the cost of prescription drugs including allowing generic drug manufacturers to sue brand-name manufacturers for not selling them samples for testing necessary to get to market; and requiring a drug manufacturer to submit a report to the Secretary of Health and Human Services for each price increase of certain drugs of which the wholesale acquisition cost increase is equal to 10 percent or more over a 12-month period or 25 percent or moreover a 36-month period. Dementia and Alzheimers Disease. S. 2076/H.R. 4256, Building Our Largest Dementia Infrastructure for Alzheimers Act (BOLD Act): Proposal to apply a public health approach to combat Alzheimers disease and related dementias. Medicare Observation Status. H.R. 1682/S. 753, the Improving Access to Medicare Coverage Act of 2019: Proposal to count days in the hospital in observation status toward meeting the three-day prior hospitalization requirement for skilled nursing facility care eligibility. Generic Drug Introduction. Generic Drug Introduction. H.R. 965, the CREATES Act: Proposal to speed the introduction of generic competition by curbing brand drug maker abuses of safety procedures as a means to limit generic manufacturer access to the drug samples needed to obtain Food and Drug Administration approval. Health Care Rights Law. Proposed rule to the provision of the Affordable Care Act addressing discrimination based on age, race, color, national origin, English proficiency, disability or sex. Medicaid Home and Community-Based Services: H.R. 1839, the Medicaid Services Investment and Accountability Act of 2019: Proposal extending the spousal impoverishment protections for home and community-based services until September 2019. Medicare Prescription Drug Costs. (No bill.) Proposals to reduce amount drug manufacturers must contribute to closing the donut hole in 2019. Medicare Prescription Drug Costs. (No bill.) Provisions of the United States-Mexico-Canada Agreement (formerly the North American Free Trade Agreement) addressing countries having expansive regulatory approval monopolies for biologic drugs and restricting the ability of Congress to reform patent laws that drive up drug costs for Medicare. Medicare Coverage Expansion. H.R. 576, the Seniors Have Eyes, Ears, and Teeth Act of 2019; H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act of 2019; H.R. 1518, the Medicare Hearing Aid Coverage Act of 2019: Proposals to expand Medicare coverage to include, vision, dental and hearing benefits. Medicare Open Enrollment. (No bill.) Proposals to ensure the Centers for Medicare and Medicaid Services conducts open enrollment in a way that is unbiased toward the traditional program. Medicare Part D. (No bill.) Proposals to add an out-of-pocket cap, rationalize the structure of the Part D program, and make the Part D low-income subsidy more generous. Medigap Reform: H.R. 1394, the Medigap Consumer Protection Act: Proposal to improve quality of coverage and access to Medigap by restoring first dollar coverage and extending guaranteed issue to disabled people and other beneficiairies. Drug Safety. S. 1895, the Lower Health Care Costs Act of 2019: Proposal to remove requirement that medicines marketed in the U.S. adhere to quality standards established by the U.S. Pharmacopeia. These standards allow biosimilar makers to achieve regulatory certainty and expedite biosimilars to market. Medicare Enrollment. H.R. 2477/S. 1280, the BENES Act of 2019: Proposal to improve beneficiary education tools and extend funding for state health insurance and assistance programs. Reducing Health Care Costs: S. 1895, the Lower Health Care Costs Act of 2019: Proposal to eliminate surprise medical billing including out-of-network charges in emergencies. | Administration on Aging,Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Labor, Dept of (DOL),Natl Economic Council (NEC),Office of Management & Budget (OMB),SENATE,Social Security Administration (SSA),Treasury, Dept of | 190000 | 0 | 0 | 2019-10-07T10:29:25.720000-04:00 |